As of June 14, 2025, Evelo Biosciences Inc (EVLO) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Evelo Biosciences Inc's Gross Margin to Peers
To better understand Evelo Biosciences Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Evelo Biosciences Inc (EVLO) | 7775.20% |
| Syros Pharmaceuticals Inc (SYRS) | 7775.20% |
| IVERIC bio Inc (ISEE) | 7775.20% |
| Dyne Therapeutics Inc (DYN) | 7775.20% |
| IDEAYA Biosciences Inc (IDYA) | 7775.20% |
| Inozyme Pharma Inc (INZY) | 7775.20% |
Compared to its competitors, Evelo Biosciences Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.